Mobility Global grants new stock awards to executives
Mobility Global Inc. announces restricted stock unit awards for executives, highlighting a strategic focus on leadership incentives in the business services sector.
Gyre Therapeutics announces new employment agreements for CEO, CFO
Gyre Therapeutics, Inc. secures leadership with new agreements for CEO Ying Luo and CFO Thomas Eastling, emphasizing stability in the pharmaceutical sector.
AquaBounty Technologies Reports Key Updates in 8-K Filing
AquaBounty Technologies files an 8-K with significant updates impacting operations and the fishing industry, signaling potential shifts in market dynamics.
Golub Capital Private Credit Fund Announces October Distributions
Golub Capital Private Credit Fund reveals its October 2026 distributions for Class I and Class S shares, emphasizing commitment to shareholder returns.
Aardvark Therapeutics shares new data from HERO trial
Aardvark Therapeutics announces exploratory efficacy data from its HERO trial, potentially impacting the pharmaceutical preparations industry.
Forgent Power Solutions clarifies CFO departure details
Forgent Power Solutions clarifies the departure of CFO Ryan Fiedler, stating it was not due to disagreements, potentially boosting investor confidence.
GigCapital9 Corp. files 8-K report on recent developments
GigCapital9 Corp. has filed an 8-K report detailing recent developments, signaling ongoing activity in the blank check industry.
Climb Bio reports Phase 2 data for budoprutug in kidney disease
Climb Bio, Inc. announces promising Phase 2 trial data for budoprutug, an anti-CD19 monoclonal antibody, in treating primary membranous nephropathy.
Armour Residential REIT announces $0.24 cash dividend for Nov 2026
Armour Residential REIT, Inc. declares a cash dividend of $0.24 per share for November 2026, reflecting its commitment to shareholder value.
reAlpha Tech updates director compensation policy
reAlpha Tech Corp. revises its non-executive director compensation policy to enhance competitiveness in the real estate sector.
ENB Financial Corp declares fourth-quarter cash dividend
ENB Financial Corp announces a $0.19 cash dividend for Q4 2026, marking a $0.01 increase from the prior quarter, payable on December 15, 2026.
SLM Student Loan Trust 2005-7 faces failed remarketing of notes
SLM Student Loan Trust 2005-7 announces a failed remarketing of its class A-5 notes, requiring noteholders to retain their investments.
Edesa Biotech boosts executive salaries amid growth plans
Edesa Biotech increases salaries for CEO and executives, signaling confidence in future growth and stability in the pharmaceutical preparations industry.
SLM Student Loan Trust 2005-5 Faces Failed Remarketing of Notes
SLM Student Loan Trust 2005-5's class A-5 notes face a failed remarketing, impacting noteholders and highlighting challenges in asset-backed securities.
60 Degrees Pharmaceuticals updates investor presentation
60 Degrees Pharmaceuticals updates its investor presentation, enhancing communication with stakeholders and reflecting its strategic direction in the pharmaceutical sector.
Aptevo Therapeutics reports AML treatment progress with mipletamig
Aptevo Therapeutics announces that ten AML patients advanced to stem cell transplant after treatment with mipletamig, highlighting progress in cancer therapies.
Burke & Herbert Financial Services to Hold Votes Every Three Years
Burke & Herbert Financial Services Corp. will hold advisory votes on executive compensation every three years, despite shareholder preference for annual votes.
Nuveen Global Cities REIT Declares Distributions for Stock
Nuveen Global Cities REIT, Inc. has declared distributions for its common stock, reflecting its ongoing commitment to returning value to shareholders.
Sunbelt Rentals to Hold Annual Say-on-Pay Votes Following Vote
Sunbelt Rentals will conduct annual advisory votes on executive compensation, following a strong shareholder vote in favor of this approach.
Cumberland Pharmaceuticals announces positive Phase 2a trial results
Cumberland Pharmaceuticals reports encouraging Phase 2a trial results for oral ifetroban in systemic sclerosis patients, highlighting safety and tolerability.